RecruitingNCT00353483
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
Sponsor
Washington University School of Medicine
Enrollment
300 participants
Start Date
Sep 14, 2005
Study Type
OBSERVATIONAL
Conditions
Summary
The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Recently diagnosed with clinical stage II, III, or IV breast cancer
- Planning to undergo neoadjuvant or adjuvant systemic therapy; patients who have already completed neoadjuvant systemic therapy are also eligible
- Must be \>= 18 years of age
- If female, must not be pregnant
- Must not have Hepatitis B, C, or HIV
- Must be willing and able to sign informed consent document
Interventions
PROCEDUREBone marrow biopsy
PROCEDUREPeripheral blood draw
PROCEDUREBreast tissue collection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00353483
Related Trials
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807149 locations
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT0679763517 locations
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700234 locations
Longitudinal Body Composition Assessment in Breast Cancer Patients
NCT074728031 location